Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5134965 | 0.95 | HSD11B1 (0.48) | HSD11B1TSHRBCHECNR2C5AR1 | |
| SCHEMBL5072278 | 0.94 | TSHR (0.51) | HSD11B1TSHRBCHEC5AR1 | |
| SCHEMBL5070162 | 0.92 | TSHR (0.47) | HSD11B1TSHRCNR2C5AR1 | |
| SCHEMBL5137319 | 0.92 | TSHR (0.47) | HSD11B1TSHRBCHECNR2C5AR1 | |
| SCHEMBL5075074 | 0.91 | TSHR (0.46) | HSD11B1TSHRBCHE | |
| SCHEMBL5072355 | 0.90 | HSD11B1 (0.45) | HSD11B1TSHRBCHEC5AR1 | |
| SCHEMBL5136484 | 0.90 | TSHR (0.45) | HSD11B1TSHRBCHECNR2C5AR1 | |
| SCHEMBL5072498 | 0.90 | TSHR (0.45) | HSD11B1TSHRBCHEC5AR1 | |
| SCHEMBL5137360 | 0.90 | TSHR (0.45) | HSD11B1TSHRCNR2C5AR1 | |
| SCHEMBL5137316 | 0.90 | TSHR (0.45) | HSD11B1TSHRC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |